Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip
Sponsor: Pacira Pharmaceuticals, Inc
Listed as NCT03382262, this PHASE2 trial focuses on Osteoarthritis of the Hip and Osteoarthritis of the Shoulder and remains completed. Sponsored by Pacira Pharmaceuticals, Inc, it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Feb 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pacira Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .